Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NEXR vs BDRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDRX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–0 Matrix Metrics)

BDRX Overall Winner 6-Pillar Tally: NEXR 1 – 3 BDRX (2 Tie) Matrix Metrics: NEXR 0 – 7 BDRX

As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas BDRX carries 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both NEXR (31.0/100 SELL) and BDRX (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEXR vs BDRX
NEXR US Equity
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.42β · 2730% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 55.6 · SMA20: $0.94 · SMA50: $1.16
BDRX NASDAQ Head-to-Head Winner
Biodexa Pharmaceuticals plc American Depositary Shs
Pharmaceutical Preparations
$2.35
-2.29% 1D
Market Cap $1.2M
TTM Revenue $83,000
Forward P/E N/M
Beta / 30D Vol 5.72β · 2679% Vol
Unified Composite Score
34.7 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (56.6% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $2.42 · SMA50: $1.38

6-Pillar Scorecard Institutional Category Breakdown (NEXR 1 – 3 BDRX)

Columns: Metric · NEXR · BDRX
1. Valuation Multiples BDRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 15.0x
2. Growth & Scale BDRX
Revenue Growth (YoY) N/A -64.1%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $83,000
Market Cap N/A $1.2M
3. Profitability & Quality BDRX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -42.0%
4. Balance Sheet & Cash Flow NEXR
Cash Generation (TTM) N/A -$8.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $138.06 Book/Sh · -42.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEXR (0) vs BDRX (7)
Institutional Metric NEXR BDRX Criterion Row Edge
Market Capitalization
Scale
N/A $1.2M Larger Scale BDRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -64.1% Higher Growth BDRX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin BDRX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin BDRX
Return on Equity (ROE)
Capital Efficiency
N/A -42.0% Higher ROE BDRX
52-Week Range Position
Momentum
23% ($0–$5) 23% ($0–$9) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
8.42β · 2730% Vol 5.72β · 2679% Vol Lower Realized Risk BDRX
Unified Institutional Score
Composite Signal
31.0 / 100 (SELL) 34.7 / 100 (SELL) Higher Composite BDRX
Trailing 12M Revenue (USD)
Operating Scale
N/A $83,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 15.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$8.8M EBITDA ($138.06 Book/Sh · -42.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDRX +346.87 pp
NEXR: +67.27% · BDRX: +414.14%
3M Horizon BDRX +116.44 pp
NEXR: -47.73% · BDRX: +68.71%
6M Horizon NEXR +26.29 pp
NEXR: +0.73% · BDRX: -25.56%
1Y Horizon BDRX +318.72 pp
NEXR: -39.21% · BDRX: +279.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEXR vs BDRX. Trailing 12-month operating profitability (NEXR N/A vs BDRX 0.0%) and valuation multiples (NEXR N/M vs BDRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NEXR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BDRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BDRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEXR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BDRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NEXR vs BDRX Key Questions & Quantitative Answers

As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas BDRX carries 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both NEXR (31.0/100 SELL) and BDRX (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

BDRX leads the Growth & Scale pillar: NEXR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BDRX at -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NEXR generates N/A in USD-normalized revenue versus $83,000 for BDRX. In operating R&D and SG&A reinvestment, NEXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BDRX.

BDRX screens cheaper on headline valuation multiples. NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.0x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEXR (N/A ROE) versus BDRX (-42.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk). By comparison, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.72β · 2679% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.